A specialized sickle cell service based at the Royal London Hospital is facing closure after a temporary six-month trial, causing concern among patients who rely on the service for managing pain crises.
This initiative, providing quick access to specialized care for individuals with sickle cell disease – a group of inherited health conditions affecting red blood cells, prevalent among those of African or Caribbean descent, is scheduled to cease operations on January 30. Patients are worried that the closure will force them to seek care at general A&E departments instead.
A petition launched by Delo Biye, a 48-year-old sickle cell patient from London, has gathered over 24,000 signatures in protest against the closure, expressing fears that lives could be endangered.
Apart from the Royal London unit, only seven similar emergency specialist sickle cell services exist nationally. NHS England has been evaluating a two-year pilot program involving emergency department bypass units, coinciding with the conclusion of these pilots as the Royal London service faces shutdown.
Delo, a frequent user of the unit for urgent care, emphasizes the superior support provided by specialist staff compared to general NHS teams, who may lack familiarity with the condition.
Calvin Campbell, a 61-year-old sickle cell patient and NHS Senior Community Ambassador in London, echoes concerns about the misunderstanding of sickle cell pain in hospitals, citing instances of poor treatment and derogatory remarks towards patients.
Despite efforts to improve sickle cell care, tragic incidents persist. Recent cases, including the deaths of Evan Nathan Smith and Dave Onawelo, highlight the ongoing challenges faced by individuals with sickle cell disease in receiving appropriate and timely medical attention.
The Sickle Cell Society, endorsing Delo’s petition, emphasizes the vital role of specialist care in addressing the unique needs of sickle cell patients and calls for sustained funding to support such services.
John James, CEO of the Sickle Cell Society, stresses the urgent need for healthcare decisions to be informed by data that prioritizes patient outcomes and supports healthcare professionals in delivering effective care.
Families and patients express apprehension over the broader trend of reducing specialist sickle cell services, despite the increasing demand and persistent disparities in care. Delo remains determined to fight against the closure of the emergency service, underscoring the critical need for continued access to specialized care.
Responding to the petition, Barts Health NHS Trust confirms the impending closure of the service at the end of January, emphasizing that patients with sickle cell disease will still receive specialist-led care at the hospital.
Sickle cell disease, a hereditary blood disorder predominantly affecting individuals of African or Caribbean descent, poses significant health risks due to the abnormal structure of red blood cells, leading to potential life-threatening complications.
For sickle cell patients, blood transfusions are a primary treatment method, with more severe cases requiring regular blood exchanges to replace abnormal blood cells with healthy donor blood.